JP2022518944A - 肺動脈性肺高血圧症を治療するための投与レジメンおよび方法 - Google Patents

肺動脈性肺高血圧症を治療するための投与レジメンおよび方法 Download PDF

Info

Publication number
JP2022518944A
JP2022518944A JP2021544351A JP2021544351A JP2022518944A JP 2022518944 A JP2022518944 A JP 2022518944A JP 2021544351 A JP2021544351 A JP 2021544351A JP 2021544351 A JP2021544351 A JP 2021544351A JP 2022518944 A JP2022518944 A JP 2022518944A
Authority
JP
Japan
Prior art keywords
kar5585
dose
day
kar5417
auc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021544351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518944A5 (enExample
Inventor
ミシェル パラシオス，
エリック ジェイ． ゴーケル，
スティーブン エー． リング，
マグダレーナ アロンソ－ガリシア，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altavant Sciences GmbH
Original Assignee
Altavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altavant Sciences GmbH filed Critical Altavant Sciences GmbH
Publication of JP2022518944A publication Critical patent/JP2022518944A/ja
Publication of JP2022518944A5 publication Critical patent/JP2022518944A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021544351A 2019-01-30 2020-01-30 肺動脈性肺高血圧症を治療するための投与レジメンおよび方法 Pending JP2022518944A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962798827P 2019-01-30 2019-01-30
US62/798,827 2019-01-30
PCT/IB2020/000074 WO2020157577A1 (en) 2019-01-30 2020-01-30 A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl

Publications (2)

Publication Number Publication Date
JP2022518944A true JP2022518944A (ja) 2022-03-17
JP2022518944A5 JP2022518944A5 (enExample) 2022-12-19

Family

ID=70285725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544351A Pending JP2022518944A (ja) 2019-01-30 2020-01-30 肺動脈性肺高血圧症を治療するための投与レジメンおよび方法

Country Status (9)

Country Link
US (2) US11607413B2 (enExample)
EP (1) EP3917531A1 (enExample)
JP (1) JP2022518944A (enExample)
KR (1) KR20210133953A (enExample)
CN (1) CN113557022A (enExample)
AU (1) AU2020213746A1 (enExample)
CA (1) CA3128327A1 (enExample)
MX (1) MX2021009055A (enExample)
WO (1) WO2020157577A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3119912A1 (en) * 2018-11-14 2020-05-22 Altavant Sciences Gmbh A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin
US11413287B2 (en) * 2018-11-16 2022-08-16 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
WO2020128614A1 (en) * 2018-12-17 2020-06-25 Altavant Sciences Gmbh Method for treating interstital lung disease
MX2021009055A (es) 2019-01-30 2021-10-22 Altavant Sciences Gmbh Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo.
AU2020244278A1 (en) * 2019-03-15 2021-09-30 Altavant Sciences Gmbh A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
WO2023062595A1 (en) 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875622B2 (en) 2007-07-11 2011-01-25 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
CA3119912A1 (en) * 2018-11-14 2020-05-22 Altavant Sciences Gmbh A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin
US11413287B2 (en) 2018-11-16 2022-08-16 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
WO2020128614A1 (en) 2018-12-17 2020-06-25 Altavant Sciences Gmbh Method for treating interstital lung disease
WO2020128608A1 (en) 2018-12-17 2020-06-25 Altavant Sciences Gmbh Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension
MX2021009055A (es) 2019-01-30 2021-10-22 Altavant Sciences Gmbh Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo.
AU2020244278A1 (en) * 2019-03-15 2021-09-30 Altavant Sciences Gmbh A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 195, JPN6023047662, 2017, pages 4193, ISSN: 0005367982 *

Also Published As

Publication number Publication date
KR20210133953A (ko) 2021-11-08
CN113557022A (zh) 2021-10-26
US11607413B2 (en) 2023-03-21
US20200237759A1 (en) 2020-07-30
CA3128327A1 (en) 2020-08-06
EP3917531A1 (en) 2021-12-08
WO2020157577A8 (en) 2020-10-15
AU2020213746A1 (en) 2021-08-19
US20240041877A1 (en) 2024-02-08
MX2021009055A (es) 2021-10-22
WO2020157577A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
JP2022518944A (ja) 肺動脈性肺高血圧症を治療するための投与レジメンおよび方法
Matera et al. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease
EP2838517B1 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
EA020193B1 (ru) Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh)
JP5978216B2 (ja) テオフィリンとフェブキソスタットの併用療法のための方法
JP7670461B2 (ja) 過活動膀胱の治療のためのビベグロンの投薬
CN104066324A (zh) 治疗痛风急性发作的方法
JP6145946B2 (ja) 併用ａｌｓ療法
KR20240136361A (ko) 약학적 건조 분말 흡입 제제
JP2012501301A (ja) ガボキサドールおよびｐａｔ１阻害薬またはｏａｔ阻害薬を含む医薬組成物
EP3302483B1 (en) Pharmaceutical compositions and use thereof
JP2022549137A (ja) イブジラスト経口製剤およびその使用方法
US9763939B2 (en) Compositions and methods for treating mitochondrial diseases
HK40062167A (en) A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl
JP2023539788A (ja) 口内乾燥症の治療剤
CN111526875A (zh) 用于治疗骨关节炎疼痛的mPGES-1抑制剂
WO2025218795A1 (zh) 一种药物组合物及其应用
WO2025218797A1 (zh) 一种胶囊或固体制剂及其应用
HK40114255A (en) Use of vibegron to treat overactive bladder
WO2023170107A1 (en) Pi3k/akt/mtor inhibitor for improving the cellular uptake of a radiopharmaceutical
EA052842B1 (ru) Твердые фармацевтические композиции адаграсиба
CN120899911A (zh) JAK抑制剂或Janus激酶蛋白降解剂治疗纤维化的用途和方法
TW201919704A (zh) 利用吡啶斯的明（pyridostigmine）及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法
HK40025703A (en) Mpges-1 inhibitor for the treatment of osteoarthritis pain
HK1207285B (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221209

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240710